NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
NCT02066883: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors |
|
|
| Recruiting | N/A | 150 | RoW | | Cancer Centre of Monoclonal Therapy, LLC | Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Lymphocytic Leukemia, Burkitt's Lymphoma | 07/15 | 02/17 | | |